Advertisement
The Lancet Gastroenterology and Hepatology
Advanced Search

Browse By Issue

List of Issues

About The Lancet Gastroenterology & Hepatology

Register
Subscribe
Submit

About the journal

The Lancet Gastroenterology & Hepatology launched in September, 2016, and is a monthly journal of original research, review, opinion, and news covering international issues relevant to gastroenterologists and hepatologists worldwide.

Reputation and Impact

The Lancet Gastroenterology & Hepatology has an Impact Factor of 14.789® and ranks fifth among clinical gastroenterology and hepatology journals (2019 Journal Citation Reports®, Clarivate Analytics 2020). The journal is the foremost journal for clinically focused research in its category. The Lancet Gastroenterology & Hepatology provides a clear, authoritative, and independent forum for the highest quality clinical research in gastroenterology and hepatology, together with reviews, opinion, and news.

The journal publishes papers that reflect the rich variety of ongoing clinical research in gastroenterology and hepatology, in particular (but not limited to) in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.

As with other journals in the Lancet family, The Lancet Gastroenterology & Hepatology offers a fast-track publication process in which papers can be published online within 4–8 weeks from submission. The journal is indexed/abstracted in MEDLINE/PubMed, Scopus, and in the Journal Citation ReportsTM.

Information for Authors

The Lancet Gastroenterology & Hepatology publishes interesting and informative reviews on any topic connected with gastroenterology or hepatology, and considers any original research contribution that advocates change in, or illuminates, clinical practice in these areas. Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal. All papers should be written to be clearly understandable to the journal’s readers in a wide range of specialties and countries.

The journal publishes a range of article types that encompass all aspects of gastroenterology and hepatology medicine: Comment, Correspondence, News, Article, Review, Health Policy, Viewpoint, and Clinical Picture.

All original research judged eligible for consideration by the journal’s editors will be peer-reviewed within 72 h and, if accepted, published within 8 weeks from submission. All accepted Articles will be published online first before appearing in the print journal.

The Lancet journals are signatories of the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, issued by the International Committee of Medical Journal Editors (ICMJE Recommendations) and to the Committee on Publication Ethics (COPE) code of conduct for editors. We follow COPE's guidelines.

If your question is not addressed on these pages then the journal’s editorial staff will be pleased to help (+44 [0] 20 7424 4950). Alternatively, email the Editor at [email protected]

About our content

We publish papers relating to primary and secondary prevention, diagnosis, management, and treatment of any disease or disorder of the alimentary tract, liver, gallbladder, biliary tree, and exocrine pancreas and their complications. In addition, the journal continues The Lancet’s tradition of advocacy and health policy and aims to catalyse alliances between health-care professionals, the public, and policy makers to champion change based on the best evidence to deliver better health worldwide.

Manuscript submission

To submit your manuscript to The Lancet Gastroenterology & Hepatology please visit http://www.editorialmanager.com/thelancetgastrohep.

Publishing excellence

As trusted sources of information, the Lancet journals set extremely high standards for publishing, and we are committed to ensuring that our editorial processes meet our standards of excellence. From acceptance of your paper through to publication and beyond, our in-house teams of professional Editors, Assistant Editor, Illustrators, Production Editors, and Marketing and Communications experts can provide personal attention and guidance to strengthen the accuracy, accessibility, timeliness, and impact of your research.

About the Editorial team

Rob Brierley, Editor-in-Chief

I studied molecular and cellular biochemistry and clinical pharmacology at the University of Oxford, and clinical oncology at the University of Birmingham. After graduation, I was a technical editor for the Journal of Molecular Biology, and worked on a series of viral hepatitis textbooks, before joining The Lancet group in 2004. After positions at The Lancet Infectious Diseases and The Lancet, I joined The Lancet Oncology in 2008, becoming Deputy Editor in 2012, before launching The Lancet Gastroenterology & Hepatology in 2016. My interests include gastrointestinal and hepatobiliary cancers, viral hepatitis, and inflammatory bowel diseases.

Hugh Thomas
Hugh Thomas, Deputy Editor

I studied medical genetics at Swansea University, and the developmental origins of metabolic disease at the University of Southampton. In 2015 I joined Nature Reviews Gastroenterology & Hepatology as an assistant editor, becoming associate editor in 2016 and senior editor in 2018. After a year working as a medical writer, I joined The Lancet Gastroenterology & Hepatology as Deputy Editor in 2020. My interests include MAFLD, inflammatory bowel diseases, and public health.

Sheila Pinion, Senior Editor

I studied biomedical sciences at Royal Holloway, University of London, and stem cells and regeneration at the University of Bristol. I joined The Lancet group in 2016 as an Assistant Editor, most recently working on secondment as acting Senior Editor at The Lancet Oncology and The Lancet Respiratory Medicine. I joined The Lancet Gastroenterology & Hepatology as Senior Editor in 2019.

International Advisory Board

The International Advisory Board of The Lancet Gastroenterology & Hepatology consists of key opinion leaders and researchers who lend their expertise to this journal. We are very grateful for their support and advice on editorial matters.

Ombudsman

Our ombudsman can: investigate delays in handling submitted manuscripts; discourtesy; failure to follow outlined procedures; failure to take reasonable account of representations to us by authors and readers; and challenges to the publishing ethics of the journal. If you have concerns about any of the above, please first contact an editor or the editorial inbox [email protected]; an editor will then respond to you (often, an editor can respond satisfactorily). If you remain dissatisfied with our response, please contact Malcolm Molyneux ([email protected])

Read more about the ombudsman and see our ombudsman's reports.

The Lancet Group’s Diversity Pledge and No All-Male Panel Policy

Read the Diversity Pledge and No All-Male Panel Policy

Cover image volume 5, Issue 11
November 2020
Volume 5, Issue 11